The SEC is litigating what some observers are a calling a first-of-its-kind insider trading case against a pharma executive who allegedly bought stock in a rival company after hearing that his own company was about to be acquired.
Compliance Hot Spots: SEC Pursues Novel Insider Trading Case + 'Hypocrisy' in White-Collar Crime Response + SDNY Vet Leads Russia Sanctions Task Force
Leave a Reply